All In Biotech

Drug Trial Radar · NCT00252863

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study

Last checked: Nov 20, 2026Latest source record: Mar 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,600

Actual

Start

Dec 2004

Primary completion

Not stated

Study completion May 2006

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the local German treatment guidelines.

Conditions

  • Asthma

Interventions

  • Symbicort, used twice daily (b.i.d) and as needed (prn)Drug

  • Budesonide Turbuhaler 200 µgDrug

  • Fluticasone Discus 250 µgDrug

  • Formoterol Turbuhaler 4.5 µgDrug

  • Terbutaline Turbuhaler 0.5 mgDrug

  • Salbutamol pressurized metered dose inhaler (pMDI) 100 µgDrug

  • Salmeterol Discus 50 µgDrug

  • Budesonide/Formoterol Turbuhaler 160/4.5 µgDrug

  • Fluticasone/Salmeterol Discus 250/50 µgDrug

  • Fluticasone/Salmeterol Discus 500/50 µgDrug

  • Theophylline 200 mgDrug

  • Theophylline 300 mgDrug

  • Singulair 10 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first severe asthma exacerbation

Locations

169 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Amberg, Germany

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Auerbach, Germany

  • Research Site

    Augsburg, Germany

  • Research Site

    Backnang, Germany

  • Research Site

    Bad Arolsen, Germany

  • Research Site

    Bad Doberan, Germany

  • Research Site

    Bad Lippspringe, Germany

  • Research Site

    Bad Neuenahr, Germany

  • Research Site

    Bad Reichenhall, Germany

  • Research Site

    Bad Sessendorf, Germany

  • Research Site

    Bayreuth, Germany

  • Research Site

    Bensheim, Germany

  • Research Site

    Bergisch Gladbach, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Bitte Eintragen, Germany

  • Research Site

    Bochum, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Borna, Germany

  • Research Site

    Brake, Germany

  • Research Site

    Burg, Germany

  • Research Site

    Burgwedel, Germany

  • Research Site

    Castrop-Rauxel, Germany

  • Research Site

    Chemnitz, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Coswig, Germany

  • Research Site

    Cottbus, Germany

  • Research Site

    Damme, Germany

  • Research Site

    Darmstadt, Germany

  • Research Site

    Deggendorf, Germany

  • Research Site

    Dillingen, Germany

  • Research Site

    Dinslaken, Germany

  • Research Site

    Dortmund, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Dülmen, Germany

  • Research Site

    Düsseldorf, Germany

  • Research Site

    Eisenach, Germany

  • Research Site

    Eisenhüttenstadt, Germany

  • Research Site

    Emden, Germany

  • Research Site

    Erfurt, Germany

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.